1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Amylases

Amylases

Amylases are crucial enzymes which hydrolyze internal glycosidic linkages in starch and produce as primary products dextrins and oligosaccharides. Amylases are classified into α-amylase, β-amylase, and glucoamylase based on their three-dimensional structures, reaction mechanisms, and amino acid sequences. Amylases have innumerable applications in clinical, medical, and analytical chemistries as well as in food, detergent, textile, brewing, and distilling industries.

Amylases Related Products (77):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-178170
    α-Amylase/α-Glucosidase-IN-22
    Inhibitor
    α-Amylase/α-Glucosidase-IN-22 is an inhibitor of α-Amylase and α-Glucosidase with IC50 values of 1.71 and 10.36 nM (5 and 23.8 folds more potent than Acarbose (HY-B0089)). α-Amylase/α-Glucosidase-IN-22 can be used for the researches of metabolic disease, such as diabetes.
    α-Amylase/α-Glucosidase-IN-22
  • HY-168185
    α-glucosidase/PTP1B-IN-1
    Inhibitor
    α-glucosidase/PTP1B-IN-1 (compound 8a) is a potent α-glucosidase and PTP1B inhibitor with an IC50 value of 66.3 μM and 47.0 μM, respectively. α-glucosidase/PTP1B-IN-1 exhibits excellent activities against α-amylase with an IC50 of 30.62 μM. α-glucosidase/PTP1B-IN-1 can dock into the active pockets of α-glucosidase and PTP1B. α-glucosidase/PTP1B-IN-1 has potential to reduce the postprandial blood glucose and is used for Type 2 diabetes mellitus.
    α-glucosidase/PTP1B-IN-1
  • HY-162036
    α-Amylase/α-Glucosidase-IN-7
    Inhibitor
    α-Amylase/α-Glucosidase-IN-7 (Compound 3f) is a competitive α-glucosidase and α-amylase enzyme inhibitor with IC50 values of 18.52 and 20.25 µM, respectively. α-Amylase/α-Glucosidase-IN-7 can also effectively inhibit AChE and BChE, with IC50 values of 9.25 and 10.06 µM respectively. α-Amylase/α-Glucosidase-IN-7 can be used in diabetes and Alzheimer’s research.
    α-Amylase/α-Glucosidase-IN-7
  • HY-162169
    α-Amylase/α-Glucosidase-IN-8
    Inhibitor
    α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC50 = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes.
    α-Amylase/α-Glucosidase-IN-8
  • HY-143268
    HPA-IN-1
    Inhibitor
    HPA-IN-1 (Compound 1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC50 values of 12.0 μM and 410.4 μM against HPA and α-glucosidase, respectively.
    HPA-IN-1
  • HY-N11844
    Quercetin 3-(6″-caffeoylsophoroside)
    Inhibitor
    Quercetin 3-(6″-caffeoylsophoroside) is an orally active α-amylase inhibitor, with an IC50 of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research.
    Quercetin 3-(6″-caffeoylsophoroside)
  • HY-154972
    α-Amylase/α-Glucosidase-IN-3
    Inhibitor
    α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC50s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus.
    α-Amylase/α-Glucosidase-IN-3
  • HY-161429
    Antidiabetic agent 5
    Inhibitor
    Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and α-amylase with IC50 values of 3.91,8.89 μM,respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes.
    Antidiabetic agent 5
  • HY-133718
    Acarviosin
    Acarviosin, a pseudodisaccharide moiety, is a part of the potent inhibitor of α-amylase.
    Acarviosin
  • HY-178363
    α-Amylase-IN-13
    Inhibitor
    α-Amylase-IN-13 is an orally active, selective, brain-penetrant α-amylase inhibitor (IC50 = 0.71 μM). α-Amylase-IN-13 inhibits α-amylase through a mixed type of inhibition mechanism. α-Amylase-IN-13 leads to a significant reduction in blood glucose level in diabetic rats. α-Amylase-IN-13 causes significant histopathological improvements in the kidney, liver, and pancreas. α-Amylase-IN-13 can be used for the study of diabetic complications.
    α-Amylase-IN-13
  • HY-N0668R
    Rubusoside (Standard)
    Inhibitor
    Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
    Rubusoside (Standard)
  • HY-N14506
    Gibbestatin B
    Inhibitor
    Gibbestatin B inhibits the expression of α-amylase induced by gibberellin in De-embryoned rice and barley (IC50 is 25-50 ppm), and has no anti-bacterial, anti-yeast and anti-fungal effects at 100 ppm.
    Gibbestatin B
  • HY-113159A
    Docosapentaenoic acid (22n-3) sodium
    Inhibitor
    Docosapentaenoic acid (22n-3) sodium is a component of phospholipids. Docosapentaenoic acid 22n-3 sodium has inhibitory activity against α-amylase and α-glucosidase, with IC50s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 sodium increases cell vitality. Docosapentaenoic acid 22n-3 sodium has a weak anti-inflammatory effect.
    Docosapentaenoic acid (22n-3) sodium
  • HY-170796
    α-Amylase-IN-11
    Inhibitor
    α-Amylase-IN-11 (compound C5f) is an α-Amylase inhibitor (IC50=0.56 μM) that can reduce the sugar level in vivo. α-Amylase-IN-11 has a moderate inhibitory effect on α-glucosidase (α-glucosidase), with IC50=11.03 μM. α-Amylase-IN-11 can significantly reduce the glucose concentration in a mouse model and has the potential for use in diabetes research.
    α-Amylase-IN-11
  • HY-170548
    α-Amylase-IN-10
    Inhibitor
    α-Amylase-IN-10 (Compound 15n) is an inhibitor for α-Amylase with an IC50 of 5.00 µM. α-Amylase-IN-10 can be used for research of type 2 diabetes mellitus.
    α-Amylase-IN-10
  • HY-162635
    α-Amylase/α-Glucosidase-IN-14
    Inhibitor
    α-Amylase/α-Glucosidase-IN-14 (compound 6E) is an oral bioactive inhibitor of α-amylase and α-glucosidase, with the IC50s of 45.53 μM and 27.73 μM, respectively.
    α-Amylase/α-Glucosidase-IN-14
  • HY-161782
    α-Amylase-IN-7
    Inhibitor
    α-Amylase-IN-7 (Compound 6e) is an inhibitor for α-Amylase with an IC50 of 40 μM. α-Amylase-IN-7 exhibits potential as an antidiabetic agent.
    α-Amylase-IN-7